The total scores for CRC patients with KRAS mutations can be computed to estimate the 1-, 3-, and 5-year survival rates, which would assist clinicians in assessing the risk of these patients in clinical practice (Figure 3). This evidence concerns the gene KRAS and colorectal carcinoma.